Evotec AG (Frankfurt:EVT) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: "This is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years."
Machine learning models identify immunophenotypes in NSCLC for immunotherapy guidance